Bits in Bio and Nucleate Present: What Is a Dead Drug Program Worth? AI from Preclinical to the Clinic
βπ What is a dead drug program worth?
βAI companies are now buying data from failed drug programs: Phase 1 readouts, patient-level biomarkers, even the slide decks explaining why a program stopped.
βWith discovery quickly being priced to zero, the next hurdle for AI is preclinical and clinical development. The data to get there is sitting in shelved programs.
βBut how will AI actually help?
βWe're bringing together three experts across the preclinical, clinical, and post-clinical sides of drug development to talk about where AI is already changing decisions.
βπ§ͺ Preclinical
The FDA has started phasing out some animal testing requirements. What can AI and human-cell models actually replace before IND, and what still needs an animal?
βπ₯ Clinical
Digital twins that let trials run with fewer patients, using a method regulators have already accepted.
βπ Post-clinical
Turning the trial data a company already owns into better patient selection and the next study design.
βThe questions: What data actually makes these models better? Who owns it? And what is a dead program worth?
βπ€ Speakers
βRoopa Ramamoorthi, PhD, PMP | Director, Catalyst Program and InVent Fund, UCSF
βLeads UCSF's Catalyst Program and InVent Fund, where she has spent 10 years
βPreviously led WIPO Re:Search partnering at BioVentures for Global Health, matching researchers with pharma resources for neglected diseases, TB and malaria
βFormer Senior Scientist at Bayer, with work spanning purification development, viral validation, and external collaborations
βUSPTO registered patent agent and PMP certified project manager
βJon Walsh, PhD | Co-founder and CSO, Unlearn.AI
βPhysicist, with a PhD from the University of Washington and a postdoc at UC Berkeley
βCo-founded Unlearn in 2017
βLeads its work bringing digital twins into drug development and through regulators
βElena Cassidy, PhD | CEO and Co-founder, Omabit
βMolecular biology PhD, Moscow State University
βCo-developed a 9-cancer early detection assay at Avida Biomed (acquired by Agilent)
βLed a rare disease assay at Natera
βModerator: Yizi Mao, PhD | Co-Managing Director, Nucleate Bay Area
βPostdoc at UC Berkeley, building high-throughput single-cell multi-omics sequencing methods
βPreviously a postdoc at the University of Washington in DNA sequencing technology
βPhD in Biochemistry, University of Nebraska-Lincoln
βποΈ Schedule
β6:00 PM | Doors open, food and drinks π
β6:45 PM | Welcome from Bits in Bio SF
β6:50 PM | Panel
β7:35 PM | Audience Q&A
β7:50 PM | Networking
β8:30 PM | Close
βπ₯ Who should come
Scientists, engineers, founders, and investors working in:
βPreclinical development, safety and tox
βTranslational science and clinical development
βBiostatistics and AI for drug development
ββ οΈ Space is limited. Registration requires approval.
βπ Thank you
Fenwick for hosting. Fenwick is a law firm serving technology and life sciences companies.
Nucleate Bay Area for helping bring this together.
β𧬠About Bits in Bio
Bits in Bio is a community connecting the bioeconomy across software, AI, and biology, with more than 12,000 members. We host meetups, Q&As with industry leaders, hackathons, and networking events in chapters around the world.
